Novel Resveratrol-Based Aspirin Prodrugs: Synthesis, Metabolism, and Anticancer Activity

Journal of Medicinal Chemistry

Volumn 58, Issue 16, 2015, Pages 6494-6506

  Zhu, Yingdong ^a   Fu, Junsheng ^a,b   Shurlknight, Kelly L ^a   Soroka, Dominique N ^a   Hu, Yuhui ^c   Chen, Xiaoxin ^c   Sang, Shengmin ^a  

^a NORTH CAROLINA A AND T STATE UNIVERSITY   (United States)

^b FUJIAN AGRICULTURE AND FORESTRY UNIVERSITY   (China)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,5 DIMETHOXYSTYRYL) 4 BROMOBENZENE; 1,3 DIMETHOXY 5 VINYLBENZENE; 2 (4 BROMOPHENYL) 1 (2 HYDROXYPHENYL)ETHANONE; 2 [2 (4 BROMOPHENYL)ACETYL]PHENYL ACETATE; 2 [4 (3,5 DIHYDROXYSTYRYL)PHENYL] 1 (2 HYDROXYPHENYL)ETHANONE; 2 [[4 (3,5 DIMETHOXYSTYRYL)PHENYL] (HYDROXY)METHYL]PHENOL; 3 (4 HYDROXYSTYRYL) 5 HYDROXYPHENYL 2 ACETOXYBENZOATE; 4 (3 HYDROXY 5 METHOXYSTYRYL)PHENYL 2 ACETOXYBENZOATE; 4 (3 HYDROXY 5 METHOXYSTYRYL)PHENYL 2 HYDROXYBENZOATE; 4 (3,5 DIHYDROXYSTYRYL)PHENYL 2 ACETOXYBENZOATE; 4 (3,5 DIHYDROXYSTYRYL)PHENYL 2 HYDROXYBENZOATE; 4 (3,5 DIMETHOXYSTYRYL)PHENYL 2 ACETOXYBENZOATE; 4 (3,5 DIMETHOXYSTYRYL)PHENYL 2 HYDROXYBENZOATE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; PTEROSTILBENE; RESVERATROL; RESVERATROL ASPIRIN HYBRID; UNCLASSIFIED DRUG; [4 (3,5 DIHYDROXYSTYRYL)PHENYL](2 HYDROXYPHENYL)METHANONE; [4 (3,5 DIMETHOXYSTYRYL)PHENYL](2 HYDROXYPHENYL) METHANONE; ANTIOXIDANT; CYCLINE; PRODRUG; STILBENE DERIVATIVE;

ALDOL REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SYNTHESIS; FEMALE; HCT116 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; MOUSE; NONHUMAN; STOMACH CONTENT; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; WITTIG REACTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; ASPIRIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CYCLINS; ENZYME ACTIVATION; FEMALE; HUMANS; INTESTINAL ABSORPTION; MICE; MICE, INBRED C57BL; PRODRUGS; STILBENES;

EID: 84940476354     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00536     Document Type: Article

References (43)

1. Weitz, J.; Koch, M.; Debus, J.; Hohler, T.; Galle, P. R.; Buchler, M. W. Colorectal cancer Lancet 2005, 365, 153-165 10.1016/S0140-6736(05)17706-X
2. Scarpignato, C.; Hunt, R. H. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention Gastroenterol. Clin. North Am. 2010, 39, 433-464 10.1016/j.gtc.2010.08.010
3. Elwood, P. C.; Gallagher, A. M.; Duthie, G. G.; Mur, L. A.; Morgan, G. Aspirin, salicylates, and cancer Lancet 2009, 373, 1301-1309 10.1016/S0140-6736(09)60243-9
4. Thorat, M. A.; Cuzick, J. Role of aspirin in cancer prevention Curr. Oncol. Rep. 2013, 15, 533-540 10.1007/s11912-013-0351-3
5. Thun, M. J.; Jacobs, E. J.; Patrono, C. The role of aspirin in cancer prevention Nat. Rev. Clin. Oncol. 2012, 9, 259-267 10.1038/nrclinonc.2011.199
6. Ricciotti, E.; FitzGerald, G. A. Prostaglandins and inflammation Arterioscler., Thromb., Vasc. Biol. 2011, 31, 986-1000 10.1161/ATVBAHA.110.207449
7. Dubois, R. N.; Abramson, S. B.; Crofford, L.; Gupta, R. A.; Simon, L. S.; Van De Putte, L. B.; Lipsky, P. E. Cyclooxygenase in biology and disease FASEB J. 1998, 12, 1063-1073
8. Wolfe, M. M.; Lichtenstein, D. R.; Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N. Engl. J. Med. 1999, 340, 1888-1899 10.1056/NEJM199906173402407
9. Brown, J. R.; DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention J. Clin. Oncol. 2005, 23, 2840-2855 10.1200/JCO.2005.09.051
10. Everts, B.; Wahrborg, P.; Hedner, T. COX-2-Specific inhibitors - the emergence of a new class of analgesic and anti-inflammatory drugs Clin. Rheumatol. 2000, 19, 331-343 10.1007/s100670070024
11. Antman, E. M.; Bennett, J. S.; Daugherty, A.; Furberg, C.; Roberts, H.; Taubert, K. A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association Circulation 2007, 115, 1634-1642 10.1161/CIRCULATIONAHA.106.181424
12. Kerwin, J. F., Jr.; Lancaster, J. R., Jr.; Feldman, P. L. Nitric oxide: a new paradigm for second messengers J. Med. Chem. 1995, 38, 4343-4362 10.1021/jm00022a001
13. Wallace, J. L.; McKnight, W.; Wilson, T. L.; Del Soldato, P.; Cirino, G. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils Am. J. Physiol. Gastrointest. Liver Physiol. 1997, 273, G1246-G1251
14. Lim, Y. J.; Lee, J. S.; Ku, Y. S.; Hahm, K. B. Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage J. Gastroenterol. Hepatol. 2009, 24, 1169-1178 10.1111/j.1440-1746.2009.05929.x
15. Keeble, J. E.; Moore, P. K. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs Br. J. Pharmacol. 2002, 137, 295-310 10.1038/sj.bjp.0704876
16. Rigas, B.; Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention Trends Mol. Med. 2004, 10, 324-330 10.1016/j.molmed.2004.05.004
17. Minamiyama, Y.; Takemura, S.; Nishino, Y.; Okada, S. Organic nitrate tolerance is induced by degradation of some cytochrome P450 isoforms Redox Rep. 2002, 7, 339-342 10.1179/135100002125000947
18. Basudhar, D.; Bharadwaj, G.; Cheng, R. Y.; Jain, S.; Shi, S.; Heinecke, J. L.; Holland, R. J.; Ridnour, L. A.; Caceres, V. M.; Spadari-Bratfisch, R. C.; Paolocci, N.; Velazquez-Martinez, C. A.; Wink, D. A.; Miranda, K. M. Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives J. Med. Chem. 2013, 56, 7804-7820 10.1021/jm400196q
19. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Formaldehyde, 2-butoxyethanol and 1-tert-butoxypropan-2-ol IARC Monogr. Eval. Carcinog. Risks Hum. 2006, 88, 1-478
20. Mota, K. S.; Dias, G. E.; Pinto, M. E.; Luiz-Ferreira, A.; Monteiro Souza-Brito, A. R.; Hiruma-Lima, C. A.; Barbosa-Filho, J. M.; Batista, L. M. Flavonoids with gastroprotective activity Molecules 2009, 14, 979-1012 10.3390/molecules14030979
21. Carrasco-Pozo, C.; Mizgier, M. L.; Speisky, H.; Gotteland, M. Differential protective effects of quercetin, resveratrol, rutin and epigallocatechin gallate against mitochondrial dysfunction induced by indomethacin in Caco-2 cells Chem.-Biol. Interact. 2012, 195, 199-205 10.1016/j.cbi.2011.12.007
22. Dey, A.; Guha, P.; Chattopadhyay, S.; Bandyopadhyay, S. K. Biphasic activity of resveratrol on indomethacin-induced gastric ulcers Biochem. Biophys. Res. Commun. 2009, 381, 90-95 10.1016/j.bbrc.2009.02.027
23. Quideau, S.; Deffieux, D.; Pouysegu, L. Resveratrol Still Has Something To Say about Aging! Angew. Chem., Int. Ed. 2012, 51, 6824-6826 10.1002/anie.201203059
24. Carbo, N.; Costelli, P.; Baccino, F. M.; Lopez-Soriano, F. J.; Argiles, J. M. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model Biochem. Biophys. Res. Commun. 1999, 254, 739-743 10.1006/bbrc.1998.9916
25. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 1997, 275, 218-220 10.1126/science.275.5297.218
26. Patel, K. R.; Brown, V. A.; Jones, D. J.; Britton, R. G.; Hemingway, D.; Miller, A. S.; West, K. P.; Booth, T. D.; Perloff, M.; Crowell, J. A.; Brenner, D. E.; Steward, W. P.; Gescher, A. J.; Brown, K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients Cancer Res. 2010, 70, 7392-7399 10.1158/0008-5472.CAN-10-2027
27. Juan, M. E.; Vinardell, M. P.; Planas, J. M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful J. Nutr. 2002, 132, 257-260
28. Williams, L. D.; Burdock, G. A.; Edwards, J. A.; Beck, M.; Bausch, J. Safety studies conducted on high-purity trans-resveratrol in experimental animals Food Chem. Toxicol. 2009, 47, 2170-2182 10.1016/j.fct.2009.06.002
29. Cottart, C. H.; Nivet-Antoine, V.; Beaudeux, J. L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans Mol. Nutr. Food Res. 2014, 58, 7-21 10.1002/mnfr.201200589
30. Wan, C.; Fan, J.; Zhang, J.; Wang, Z. Ortho-hydroxy assisted and copper-catalyzed oxidation of benzylic alcohol Chin. Sci. Bull. 2010, 55, 2817-2819 10.1007/s11434-010-3066-y
31. Sato, T.; Naruse, K.; Enokiya, M.; Fujisawa, T. Facile synthesis of benzyl ketones by the reductive coupling of benzyl bromide and acyl chlorides in the presence of a palladium catalyst and zinc powder Chem. Lett. 1981, 10, 1135-1138 10.1246/cl.1981.1135
32. Andrus, M. B.; Liu, J. Synthesis of polyhydroxylated ester analogs of the stilbene resveratrol using decarbonylative Heck couplings Tetrahedron Lett. 2006, 47, 5811-5814 10.1016/j.tetlet.2006.05.065
33. Azorin-Ortuno, M.; Yanez-Gascon, M. J.; Vallejo, F.; Pallares, F. J.; Larrosa, M.; Lucas, R.; Morales, J. C.; Tomas-Barberan, F. A.; Garcia-Conesa, M. T.; Espin, J. C. Metabolites and tissue distribution of resveratrol in the pig Mol. Nutr. Food Res. 2011, 55, 1154-1168 10.1002/mnfr.201100140
34. Juan, M. E.; Alfaras, I.; Planas, J. M. Colorectal cancer chemoprevention by trans-resveratrol Pharmacol. Res. 2012, 65, 584-591 10.1016/j.phrs.2012.03.010
35. Levy, G. Clinical pharmacokinetics of aspirin Pediatrics 1978, 62, 867-872
36. Cordon-Cardo, C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia Am. J. Pathol. 1995, 147, 545-560
37. Hunter, T.; Pines, J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age Cell 1994, 79, 573-582 10.1016/0092-8674(94)90543-6
38. Green, D. R.; Reed, J. C. Mitochondria and apoptosis Science 1998, 281, 1309-1312 10.1126/science.281.5381.1309
39. Desagher, S.; Martinou, J. C. Mitochondria as the central control point of apoptosis Trends Cell Biol. 2000, 10, 369-377 10.1016/S0962-8924(00)01803-1
40. Cottart, C. H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J. L. Resveratrol bioavailability and toxicity in humans Mol. Nutr. Food Res. 2010, 54, 7-16 10.1002/mnfr.200900437
41. Korsmeyer, S. J.; Wei, M. C.; Saito, M.; Weiler, S.; Oh, K. J.; Schlesinger, P. H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c Cell Death Differ. 2000, 7, 1166-1173 10.1038/sj.cdd.4400783
42. Ly, J. D.; Grubb, D. R.; Lawen, A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update Apoptosis 2003, 8, 115-128 10.1023/A:1022945107762
43. Lambert, J. D.; Sang, S.; Hong, J.; Kwon, S. J.; Lee, M. J.; Ho, C. T.; Yang, C. S. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate Drug Metab. Dispos. 2006, 34, 2111-211 10.1124/dmd.106.011460